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Breast cancer-related lymphedema (BCRL) occurs in a significant number of breast
cancer survivors as a consequence of the axillary lymphatics’ impairment after therapy
(mainly axillary surgery and irradiation). Despite the recent achievements in the clinical
management of these patients, BCRL is often diagnosed at its occurrence. In most
cases, it remains a progressive and irreversible condition, with dramatic consequences
in terms of quality of life and on sanitary costs. There are still no validated pre-surgical
strategies to identify individuals that harbor an increased risk of BCRL. However, clinical,
therapeutic, and tumor-specific traits are recurrent in these patients. Over the past few
years, many studies have unraveled the complexity of the molecular and transcriptional
events leading to the lymphatic system ontogenesis. Additionally, molecular insights are
coming from the study of the germline alterations involved at variable levels in BCRL
models. Regrettably, there is a substantial lack of predictive biomarkers for BCRL, given
that our knowledge of its molecular milieu remains extremely puzzled. The purposes of
this review were (i) to outline the biology underpinning the ontogenesis of the lymphatic
system; (ii) to assess the current state of knowledge of the molecular alterations that can
be involved in BCRL pathogenesis and progression; (iii) to discuss the present and short-
term future perspectives in biomarker-based patients’ risk stratification; and (iv) to provide
practical information that can be employed to improve the quality of life of these patients.
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INTRODUCTION
Breast cancer-related lymphedema (BCRL) is a particular form of secondary lymphedema
occurring after axillary surgical procedures and/or irradiation in 14–54% of breast cancer
survivors (1). Its clinical signs are related to an augmented volume of the upper limb due
to tissue swelling and subsequent fibrosis (2). These include impaired function and strength,
Invernizzi et al. Biology of Breast Cancer Related Lymphedema
malaise, pain, comorbidities, and psychosocial frailty (3, 4). The
diagnosis of BCRL is established by the measurement of the
arm volume. Over the past decades, a wide variety of strategies
have been proposed to identify and quantify alterations in the
upper limb volume, including tape, perometry, bioimpedance,
imaging (e.g., lymphography and magnetic resonance imaging),
and augmented reality tools (5–9). BCRL prevention is centered
on general healthcare suggestions, such as physical activity,
body weight control, skincare, avoidance of infections (10).
However, microsurgery-based primary prevention schemes, such
as axillary reverse mapping and lymphatic-venous bypass, are
showing promising results (11). For decades BCRL has been
considered as an incurable condition but several therapeutic
approaches are now available, both in the setting of physical
therapy (e.g., complex decongestive therapy, manual lymph
drainage, Qigong exercise, yoga, laser therapy, extracorporeal,
shock wave therapy) and surgery (e.g., tissue excision, derivative
microsurgery, microsurgical reconstruction, vascularized lymph
node transfer, block of sympathetic innervation) (8, 12–
15). Regrettably, the pre-surgical identification of high-risk
individuals is extremely challenging.
Despite these insights, the multifaceted biology of BCRL
remains poorly understood due to the substantial lack of
molecular data. Therefore, tailored prevention and treatment
schemes are not routinely performed in these patients. In this
review article, we seek to outline the biological and genetic
changes in the lymphatic system development and impairment
in breast cancer survivors, focusing on possible biomarkers for
its risk assessment, diagnosis, prognostication, and treatment.
PATHOPHYSIOLOGY
Ontogenesis of the Lymphatic System
The lymphatic system is composed of a complex network
of vessels and organs complementary to the cardiovascular
system (16). It plays a crucial role in several biological events,
including immune response and homeostasis of interstitial
fluids, cells, molecules, and tissue debris (17, 18). At early
stages of embryogenesis, the lymphatic vessels develop from the
embryonic veins through the stepwise expression of numerous
molecules, including prospero-related homeobox domain 1
(PROX1) and nuclear receptor subfamily 2, group F, member 2
(NR2F2) (17, 19). Interestingly, the silencing of these two genes
in mice prevents lymphangiogenesis (20, 21). The lymphatic
sac, which is lined by lymphatic endothelial cells (LECs),
represents the earliest lymphatic structure (22). The LECs express
lymphatic-specific proteins, such as vascular endothelial growth
factor C (VEGFC). The absence of this molecule in animalmodels
results in diffuse and lethal tissue swelling (23). The separation
of the lymphatic system from the blood vessels leads to the
formation of the lymphatic plexus (24). This process is mediated
by a signaling pathway in which podoplanin (PDPN), expressed
by the LECs, interacts with its receptor on platelets, promoting
their aggregation (25). Subsequently, platelet microthrombi form
a physical barrier that interrupts the communication between
lymphatic and blood vessels (26, 27). Inactivating mutations in
PDPN are related to defects in vascular system separation, and
subsequent abnormal shunts (24, 27, 28). The development of
a contractile component (i.e., myoepithelial cells) coupled with
that of a valve system allows for the unidirectional flow of
the lymph fluid. This phase is characterized by the differential
expression of PROX1, forkhead box protein C2 (FOXC2),
GATA2, integrin α9 (ITGA9), and its ligand extra domain A
fibronectin (29, 30). Their deficiency is associated with failure
in valve formation and consequent lymphedema (31–33). The
key molecular and transcriptional events in the lymphatic system
ontogenesis are outlined in Figure 1.
Fluid Drainage and Anatomic
Considerations
The lymph flow is determined by both intrinsic and extrinsic
forces that promote lymph propulsion in the lymphatic conduct;
intraluminal one-way valves minimize the backflow (34). Given
the lack of a central pump for the lymph fluid, the flow is driven
by rhythmic contractions of smoothmuscle cells in the lymphatic
vessels (35). Arterial pulsations, skeletal muscle compression,
fluctuations of central venous pressure, gastrointestinal
peristalsis, and respiration are also involved in this mechanism,
representing the passive lymph pump. The entire interstitial
drainage process is governed by the Starling equation (Figure 2).
Three types of lymphatic channels are present, namely capillaries
(also referred to as initial lymphatics), pre-collecting vessels,
and collecting vessels (Figure 3). Capillaries are blind-ending
vessels composed of a single layer of non-fenestrated LECs, with
an incomplete basal lamina. These structures have specialized
junctions and anchoring systems that act synergistically in
promoting the passage of lymph from the interstitium to the
lumen (36). Pre-collecting vessels are characterized by the
alternation of propulsion segments (i.e., provided with muscular
coat and intraluminal valves) and tracts with an absorbing
architecture (i.e., irregularly-arranged of smooth muscle cells
and discontinuous basal lamina) (37). These vessels converge
into the collecting vessels, whose functional unit is represented
by the lymphangion, defined as the segment between two valves
(38). Lymphangions have zipper-like junctions between LECs,
continuous basement membrane, well-represented muscular
layer, and bi-leaflets one-way valves (39). It should be noted that
the lymphatic network is asymmetric. Hence, the right lymphatic
duct, which drains in the right subclavian vein, is present only
in the right upper limb, the right side of the trunk, and the head
and neck region (40), while all other territories are drained by
the thoracic duct into the left subclavian vein (41).
Understanding the Tissue Milieu:
Inflammation and Matrix Response
The soft tissue composition is a key factor in lymphatic
homeostasis, as demonstrated by the increased risk of
lymphedema related to fat accumulation (8, 42, 43).
Importantly, the lymphatic fluid stasis regulates the expression
of genes with regulatory functions in adipogenesis, such as
peroxisome proliferator-activated receptor gamma (PPARG) and
CCAAT/enhancer-binding protein alpha (CEBPA) (44). Another
key factor is represented by the adiponectin, a protein hormone
involved fatty acid breakdown, that contributes to the signaling
between adipose and immune cells and regulates the chronic
inflammatory response (44). This protein can be overexpressed
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FIGURE 1 | Key molecular and transcriptional events in the lymphatic system ontogenesis. Different stages of lymphatic system development are outlined by their
distinct stage-specific expression of different molecules. LEC, lymphatic endothelial cell.
in response to lymphatic fluid stasis, thus mediating the tolerance
to proinflammatory stimuli in the case of obstruction (44, 45).
Recently, adipose-derived stem cells co-cultured with human
lymphatic endothelial cells have been shown to induce mRNA
expression of lymphatic markers and proliferation/migration
of lymphatic endothelial cells, without affecting tube formation
(46). These data pave the way for possible engineering therapies
to improve secondary lymphedema outcome.
Fibrosis and increased subcutaneous adipose tissue volume
are the two main aspects of tissue remodeling which characterize
late-stage BCRL (47). Therapeutic interventions designed to
reduce their presence can increase the lymphatic function (48).
In this respect, both cytokines and immune cells promote
lymphangiogenesis, with a subsequent potential therapeutic role
(49, 50). Interestingly, alternatively activated macrophages (M2)
are often increased in lymphedema tissues, particularly in the
setting of T helper 2 cell-mediated anti-inflammatory response in
fibrotic phases (45). The macrophage infiltration in lymphedema
decreases the overall inflammation and inhibits fibrosis (45).
It has recently been proposed that a high capillary filtration
coefficient coupled with increased plasma levels of VEGFC may
constitute important biological traits of BCRL patients (51).
Hence, a systemic increase in VEGFC promotes microvascular
permeability, and an overload of the remaining lymphatic
drainage capacity (52). On the other hand, the recovery of
interstitial fluid drainage and the natural resolution of acute
BCRL are not hindered by the administration of VEGF receptors
blockers, suggesting that these processes are lymphangiogenesis
independent. Taken together, the interstitial matrix plays a
central role in the increase of lymph drainage (53).
RISK STRATIFICATION: WHO IS LIKELY TO
DEVELOP BCRL?
Despite early detection can improve BCRL patients’ outcome,
the preventive options available to date are extremely limited
(54). The physical disruption of the arm lymphatics, such
as in case of axillary lymph node dissection (ALND), is a
well-established determinant of BCRL (55). Of note, both the
number of lymph nodes removed and the number of metastatic
lymph nodes are associated with an increased risk (56, 57). It
has been hypothesized that this could be due to the higher
dose of radiations that these patients receive in the axilla
(55, 57). Hence, radiation-induced necrosis is likely to be
involved BCRL pathogenesis (58). A higher prevalence of BCRL
has also been observed in patients treated with anti-tumor
systemic drugs, such as taxanes and trastuzumab, probably due
to diminished lymphatic contractility (59–61). The correlation
between body max index (BMI) >25 kg/m2, post-operative
weight increase, dyslipidemia, and BCRL has been widely
demonstrated (8). However, novel tumor-specific pathological
features, such as peritumoral lymphovascular invasion and the
extra-nodal extension of the metastatic deposits, have recently
been proposed to improve BCRL risk stratification (56, 57).
In general, there is a wide agreement that breast-conserving
surgery is protective against long-term complications, including
BCRL (62).
In addition to the classical mechanistic explanation, the study
of the genetics underpinning BCRL has provided intriguing
insights. Several germline alterations in genes involved at
various levels in lymphangiogenesis have been documented
in BCRL patients, suggesting a possible role for individual
predisposition in the development of lymphedema following
breast cancer therapy (Table 1). These genes include lymphocyte
cytosolic protein 2 (LCP2), spleen associated tyrosine kinase
(SYK), endothelial cell adhesion proteins (i.e., promoters, growth
factors, and their receptors), interleukins, and K-channel genes
(50, 63–72). Interestingly, these genes show recurrent somatic
alterations in breast cancer, with a higher prevalence of
gene copy-number alterations (CNAs) than somatic mutations
(Figure 4). Despite these relevant observations, no tumor-
specific recurrent molecular alterations have been identified in
BCRL patients.
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FIGURE 2 | Schematic representation of the fluid homeostasis based on the Starling equation. When the blood flow goes into the capillary, the capillary hydrostatic
pressure (Pc) and the interstitial oncotic pressure (pii) drive oxygen and nutrients toward body’s cells. Conversely, when blood moves toward venules, the interstitial
fluid hydrostatic pressure (Pi) along with the plasma oncotic pressure (pip), which are mainly applied by the surrounding proteins, drive wastes and carbon dioxide into
the capillary and subsequently out of the body.
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FIGURE 3 | Representative structure of the different types of lymphatic vessels. Small, branching lymphatic capillaries lined by a single file of lymphatic endothelial
cells (LEC) are connected to pre-collector lymphatic vessels, showing tracts with a discontinuous basal lamina. The collecting vessels, whose functional unit is the
lymphangion, are larger in diameter and have a prevalent propulsion function.
GENOMIC LANDSCAPE AND MOLECULAR
HETEROGENEITY
Genetic Determinants and Putative Driver
Alterations
It has been suggested that BCRL susceptibility might have
individual determinants, raising the possibility that therapy-
associated lymphatic injuries might heighten a pre-existing
deficit in the lymphatic function (73). Hence, among patients
with BCRL, those with the involvement of the whole arm and
hand showed an impairment of lymphatic function also in the
contralateral unaffected arm (74). Following this circumstantial
evidence, the detection of recurrent genetic traits is strategic to
achieve the goal of precision medicine in BCRL.
Lymphangiogenic and Angiogenic Genes
In the last decade, the presence of alterations in genes related
to lymphangiogenesis, lymphatic function, and permeability has
been unraveled in BCRL. One of the most studied genes is
LCP2, which is involved in the immune response through the
modulation of the T-cell signaling pathway (75). In addition,
LCP2 plays a central role in the lymphatic development,
participating in the platelet-dependent mechanism of separation
between blood and lymphatic vessels during embryogenesis
(26, 76). Alterations in this gene are related to inherited
lymphedema (77, 78). Copy-number alterations in LCP2 occur
in 1.4% of breast cancer patients (Figure 4). They show a
strong tendency toward co-occurrence with alterations in other
genes known to be implicated in BCRL, such as interleukins
(i.e., IL4, IL10, IL13) and neuropilin 2 (NRP2), as detailed
in Table 2. NRP2 is a transmembrane glycoprotein expressed
in blood and LECs, which is upregulated in the presence of
ischemia and/or hypoxia (79–81). This protein is considered
an important mediator of angiogenesis and lymphangiogenesis,
acting as a co-receptor with VEGFC. This a molecule is
encoded by two genes, namely VEGFC and Fms-related tyrosine
kinase 4 (FLT4) (82–84). Somatic alterations in NRP2, FLT4,
and VEGFC have a strong tendency of co-occurrence in
breast cancer (Table 2) and may predispose to secondary
lymphedema (68, 69, 73). Vascular cell adhesion protein 1
(VCAM1) is an adhesion molecule that promotes lymphocyte
trans-endothelial migration in cytokine activated endothelium
(85, 86). This adhesion molecule fosters tissue inflammation
and contributes to lymphedema progression. CNAs in VCAM1
occur in ∼1% of breast cancer patients (Figure 4) and they
are simultaneously present together with somatic alterations
in other genes implicated in BCRL pathogenesis (Table 2).
These include interleukins, nuclear kappa factor-beta 2 (NFKB2),
VEGFR/KDR, as well as the hepatocyte growth factor (HGF)
and its receptor MET. Six HGF/MET mutations in the sites of
interaction and binding domain, respectively, were identified in
secondary lymphedema, suggesting that altering this pathway can
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TABLE 1 | Genes that have been related to BCRL predisposition.
Genes Gene family Function
LCP2 Signal-transducing adaptor
protein
T-cell activation.
SYK Spleen tyrosine kinase Adaptive immune receptor signaling;
Cell proliferation, differentiation, and phagocytosis;
Separation of newly formed lymphatic vessels from the blood vasculature.
VCAM1 Cell adhesion promoters Vascular endothelial cell adhesion and signal transduction.
HGF, HGFR/MET, VEGFC, FLT4,
VEGFR2/KDR, NRP2
Growth factors and receptors Mitogenesis and morphogenesis;
Embryonic development;
Myocardial development;
Epithelial-mesenchymal transition;
Liver regeneration.
Cardiovascular development;
Angiogenesis;
Lymphangiogenesis;
Endothelial cell growth;
Permeability of blood vessels.
NFKB2, RORC, FOXC2 Transcription factor-coding Inflammation and immune response
Lymphoid organogenesis (in mice).
Valves development.
GJC2, GJA4 Connexins Arteriogenesis;
Oocyte survival;
Oligodendrocyte development.
IL1A, IL4, IL6, IL10, IL13 Interleukins Apoptosis and cell proliferation;
Immunoregulation and inflammation;
Expressed also in endothelial cells.
KCNA1, KCNJ3, KCNJ6, KCNK3 K channel proteins Electrochemical gradient across cell membranes;
In the lymphatic system facilitate lymph flow.
FIGURE 4 | Oncoprint visualization of the somatic molecular alterations in breast cancers (n = 3,394 samples) involving 22 genes with reported germline alterations in
BCRL patients. Each column represents a sample, each row represents a gene, as reported on the left. The genes were sorted by alterations frequency (percentage
on the left). Types of alterations and study of origin (publicly available at cBioportal.com) are color-coded on the basis of the legend on the bottom.
increase individual risk of developing lymphedema after breast
surgery and thus providing a new potential therapeutic target
(66). Another important gene in BCRL is represented by RAR-
related orphan receptor gamma (RORC), which is known to
be implicated in lymphangiogenesis, lymph node organogenesis,
immune response, and cancer (87). Regrettably, the specific
functions of this transcription factor in humans remain poorly
understood. Interestingly, both somatic missense mutations and
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TABLE 2 | Significant trends in co-occurrence between pairs within genes linked to BCRL in breast cancer public datasets available at cBioPortal.
A B Neither A not B B not A Both log2 O.R. p-value q-value
LCP2 FLT4 2756 26 35 14 >3 <0.001 <0.001
LCP2 IL13 2785 34 6 6 >3 <0.001 <0.001
LCP2 IL4 2782 34 9 6 >3 <0.001 <0.001
LCP2 GJC2 2476 27 315 13 1.92 <0.001 0.003
LCP2 IL10 2490 30 301 10 1.463 0.009 0.034
LCP2 NRP2 2737 34 54 6 >3 <0.001 0.001
NRP2 KCNA1 2687 50 84 10 2.678 <0.001 <0.001
NRP2 IL13 2762 57 9 3 >3 0.002 0.01
NRP2 IL4 2759 57 12 3 >3 0.003 0.017
NRP2 KCNJ6 2739 56 32 4 2.612 0.006 0.028
NRP2 KCNJ3 2750 57 21 3 2.785 0.013 0.045
MET NRP2 2733 38 56 4 2.361 0.011 0.039
VEGFC NRP2 2727 44 53 7 >3 <0.001 <0.001
VEGFC FLT4 2739 43 41 8 >3 <0.001 <0.001
VEGFC RORC 2465 35 315 16 1.839 <0.001 0.001
VEGFC IL10 2484 36 296 15 1.806 <0.001 0.002
SYK VCAM1 2774 29 25 3 >3 0.004 0.017
VCAM1 NFKB2 2781 25 22 3 >3 0.002 0.01
VCAM1 GJA4 2784 25 19 3 >3 0.001 0.008
VCAM1 HGF 2774 25 29 3 >3 0.004 0.017
VCAM1 IL13 2793 26 10 2 >3 0.006 0.026
VCAM1 KDR 2763 25 40 3 >3 0.008 0.033
VCAM1 IL4 2790 26 13 2 >3 0.009 0.034
VCAM1 MET 2766 23 37 5 >3 <0.001 <0.001
MET KDR 2753 35 36 7 >3 <0.001 <0.001
MET KCNA1 2700 37 89 5 2.035 0.012 0.04
HGF MET 2763 26 36 6 >3 <0.001 <0.001
SYK MET 2760 29 39 3 2.872 0.011 0.039
RORC GJC2 2377 126 123 205 >3 <0.001 <0.001
RORC IL10 2372 148 128 183 >3 <0.001 <0.001
RORC KCNA1 2432 305 68 26 1.608 <0.001 <0.001
RORC GJA4 2485 324 15 7 1.84 0.01 0.036
KDR RORC 2470 30 318 13 1.751 <0.001 0.006
FLT4 RORC 2467 33 315 16 1.925 <0.001 <0.001
NFKB2 GJA4 2787 22 19 3 >3 <0.001 0.006
NFKB2 IL10 2502 18 304 7 1.678 0.015 0.049
GJA4 IL10 2505 15 304 7 1.943 0.007 0.03
FLT4 GJA4 2763 46 19 3 >3 0.006 0.026
GJC2 IL10 2423 97 80 231 >3 <0.001 <0.001
FLT4 GJC2 2475 28 307 21 2.596 <0.001 <0.001
gene amplification in RORC are highly recurrent in breast
cancers, being detected in up to 12% of patients (Figure 4).
Alterations in this gene can be observed in patients that harbor
alterations in other BCRL genes, such as FLT4, IL10, and
VEGFR2/KDR (Table 2).
Immunomodulation and Inflammatory Response
Variations in pro-inflammatory (e.g., IL1, IL2, IL8, IL17, NFKB2)
and anti-inflammatory (e.g., IL4, IL10, IL13) cytokines have
been found in the circulating DNA of patients with BCRL
(50). Among these, the single nucleotide polymorphisms (SNPs)
significantly related to the development of unilateral arm
swelling are those targeting NFKB2, IL10, and IL4. In particular,
NFKB2 is a transcription factor involved in a multitude of
biological processes, including (but not limited to) angiogenesis,
cell proliferation, inflammation, tumorigenesis, and tumor
progression (88). Alterations in this gene are relatively rare
(∼0.8%) in breast cancers and display the strong propensity
toward co-occurrence with those targeting IL10, that are highly
recurrent (12%), as shown in Figure 4 and Table 2. IL10 is
an anti-inflammatory cytokine that acts downregulating the
expression of Th1 cytokines, MHC class II antigen-presenting
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molecules, and costimulatory molecules on macrophages (48).
In particular, IL10 influences active transcription factor binding
sites that are involved in lymphangiogenesis. Most importantly,
this interleukin induces immunosuppression and tumor escape
from immune surveillance, particularly in breast cancers lacking
the expression of the estrogen receptor (89). Alterations in IL4
have also been detected in the circulating DNA of BCRL patients.
This pleiotropic cytokine is produced by CD4+ T-cells and it has
an important role in B-cell immune response modulation (48).
This pathway is thought to be involved in alterations observed
in lymphedematous tissues, such as fibrosis, adipose deposition,
and lymphatic dysfunction (48, 90). Interestingly, it has been
recently observed that cyclooxygenase (COX)2 and its product
prostaglandin (PG)E2 are overexpressed in breast cancer stroma,
having a possible role in lymphangiogenesis and metastatic
spread s through lymphatics (91). Specifically, PGE2 activates
the EP4 receptor in cancer cells and macrophages, promoting
local VEGF-C/D overexpression, and LECs proliferation (91). All
this information opens new avenues in BCRL risk stratification,
providing that further prospective clinical studies will be
designed to investigate whether NFKB2, IL10, IL4, and EP4
can be employed as circulating biomarkers for pre-surgical
risk assessment.
Transmembrane Diffusion and Inter-cellular
Communication
Connexins are a family of specialized transmembrane proteins
that form the gap junctions between cells (70). They are crucial
for both blood and lymphatic vessel homeostasis (70). Many
authors have suggested that connexins may be implicated in
the initial development of the lymphatic system, particularly
in the formation of the lymphatic valves and sac (92, 93).
Mutations in genes encoding the connexins 47 and 37, namely
gap junction protein gamma 2 (GJC2) and gap junction protein
alpha 4 (GJA4), have been linked to both primary and secondary
lymphedema (67, 72, 94). Intriguingly, GJC2 CNAs are highly
recurrent in breast cancer, being present in 12% of cases in
the cBioPortal, as depicted in Figure 4. Furthermore, CNAs in
GJC2 and GJA4 are significantly present together with somatic
alterations in other BCRL genes, such as RORC, IL10, and FLT4
(Table 2). So far, these gap junction proteins represent promising
biomarkers in both breast cancer and BCRL prognostication.
Membrane Action Potential and Smooth Cell
Contraction
Several potassium channel genes were found to be the target
of SNPs in the setting of secondary lymphedema. These genes
include potassium voltage-gated channel subfamilies A member
1 (KCNA1), J member 3 (KCNJ3), 2 (KCNJ6), and K member
3 (KCNK3) (71). In particular, KCNA1 is a transmembrane
protein selective for potassium-positive ions; its functions are
to shape the action potential and promote the return of the
depolarized membrane to its resting state. KCJN3 and KCJN6
are inward rectifying channels that act in an opposite way to
voltage gated-channels, supporting the flow of positively charged
potassium ions into the cell and stabilizing the resting membrane
of cells (38, 71). Finally, KCNK3 is another relevant tissue factor
that contributes to the maintenance of the resting potential,
giving rise to the background or outward leak potassium-
positive currents (38). Despite the great efforts that have been
made to determine the influence of genetic predisposition in
BCRL pathophysiology, these analyses have several limitations.
Larger sample sizes could reveal additional associations between
polymorphisms and BCRL.
Biological Characteristics of the Primary
Tumors
The possible existence of molecular indicators evaluable in a
pre-operative/operative setting remains one of the key topics
surrounding BCRL. For this aim, a search on the public
genomic database cBioPortal has been conducted to determine
whether genetic alterations associated with both congenital and
postsurgical lymphedema occurred also in breast cancer. A
correlation between lymphedema candidate genes and mutations
in the primary tumor could be useful as an indicator of
patients’ individual susceptibility, along with the well-known
treatment-related risk factors. A query was submitted in order
to search genetic alterations of literature driven genes in 2,509
breast cancer samples from METABRIC (Molecular Taxonomy
of Breast Cancer International Consortium) project. Notably,
in almost all cases genetic alterations found in candidate gene
consist of gene amplification, while previous genetic studies
individuated single nucleotide polymorphisms associated with
BCRL. Most genes were altered in a small percentage of tumor
samples, ranging from 0.1 to 2.5%. However, three of them
were amplified in at least one-fifth of the breast cancer cases.
Specifically, the RORC gene was amplified in 20%, GJC2 in 24%
and IL10 in 25% of samples.
To date, the function of RORC’s encoded protein in humans
remains poorly understood. However, there are several lines of
evidence to suggest that this gene may play a part in lymphoid
organogenesis and thymopoiesis regulation (87). In addition,
RORC protein plays a role in the expression of some clock
genes and its expression has been linked to breast cancer
survival outcomes (95). RORC overexpression seems to increase
distant metastasis-free survival in breast cancer patients (96–98).
However, given the lack of knowledge on its precise function
and interactions in humans, it is not possible to speculate
on the role of RORC in BCRL pathogenesis, preventing also
any consideration of the correlation between its amplification
and lymphedema occurrence. Connexins are widely expressed
in the normal mammary glands, where gap junctions have
distinct functions in development and homeostasis, such as
modulation of cell proliferation and lactation (99). In advanced
breast neoplasms, they are believed to increase the capacity of
tumor cells to metastasize through enhancing their invasion
and adhesion ability as well as by protecting tumor cells from
hypoxia-induced death (100–102). Furthermore, some subtypes
of connexins, namely Cx26, Cx32, and Cx43 are overexpressed in
metastatic lymph nodes of ductal carcinomas (103, 104). These
findings suggest that, in later stages, connexins facilitate the
metastatic involvement of locoregional lymph nodes. However,
further studies are required to support this hypothesis.
Immunoregulatory cytokines, such as IL10, are important
actors in tumor microenvironment associated with breast cancer.
Specifically, IL10 is a pleiotropic anti-inflammatory cytokine with
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a dual role in breast cancer, exhibiting both pro- and anti-tumor
activities (105). Its intricate molecular pattern of interactions has
not been fully elucidated yet, however, this regulatory molecule
is thought to take part in tumor initiation and progression,
promoting immunosuppression and tumor immune evasion.
IL10 predominantly displays a tumor-inhibiting activity through
the activation of NK cells, enhancement in surface expression of
MHC antigen and promoting tumor infiltration by neutrophil
and macrophages (106). In the opposite way, IL10 may also
reduce immune response against cancer, mainly decreasing the
antigen presentation capacity and modulating the production
of several cytokines. Hence, higher levels of IL10 may increase
tumor immune escape and this hypothesis is consistent with the
observation of increased IL10 concentration in serum of breast
cancer patients, particularly in case of metastatic disease (89).
Hypothesizing that gene amplification leads to an increase in
protein expression, IL10 immunosuppressive properties could
the metastatic potential of breast cancer, increasing the risk
of lymph node involvement, which represents a well-known
predisposing factor for BCLR. These assumptions on the possible
prognostic value of IL10 amplification for lymphedema risk
prediction remain largely speculative. However, some studies
found higher IL10 levels in metastatic lymph nodes and IL10
polymorphisms associated with increased expression in patients
with lymph node-positive breast cancer (107, 108). Interestingly,
high IL10 levels were also found in inflammatory breast cancer,
a particularly aggressive and highly metastatic form of breast
cancer, in which this cytokine correlates with the presence of
lymphovascular invasion (109). This parameter has been recently
associated with an increased risk of BCRL in patients with left
side localization.
In summary, there is no specific evidence to date that
genetic alterations in primary tumor play a direct role in
BCRL pathogenesis. However, the correlation between somatic
mutations and higher rates of nodal involvement could indirectly
lead to more aggressive therapeutic schemes, including ALND
and axillary radiation, and thus increasing the odds of developing
post-surgical lymphedema.
LYMPHANGIOGENESIS-RELATED
MECHANISMS AS POTENTIALLY
DRUGGABLE TARGETS
All these novel data suggest that novel individualized therapeutic
strategies can be realistically implemented. In particular,
the crucial role of VEGF and the observation of BCRL
improvement in patients treated with anti-VEGF monotherapy
provided evidence for the possible role of anti-angiogenic
drugs in lymphedema treatment (110). In particular, a pilot
study was conducted in order to evaluate the efficacy and
safety of bevacizumab, a monoclonal antibody directed against
VEGF, in patients with lymphedema following breast cancer
treatment (110). The working hypothesis was that VEGF-
inhibitors could significantly reduce interstitial fluid collection
through the modulation of vascular permeability, resulting
in an indirect improvement of lymphatic obstruction and
drainage. Preliminary study results confirmed the hypothesis
that Bevacizumab has a role in interstitial fluid pressure and
extracellular fluid volume reduction (NCT00318513). However,
many aspects limit its use in clinical practice for breast cancer
patients. To date, Bevacizumab is no longer approved for breast
cancer treatment and there is only partial evidence regarding
the use of VEGF-inhibitors in subjects without active cancer.
Lymph fluid collection represents the starting point of BCRL,
which is worsened by chronic inflammatory tissue response to
protein-rich fluid accumulation. The modulation of immune
signalmolecules, such as interleukins, could reduce inflammation
and tissue reaction, preventing lymphedema chronicization. In
this setting, a trial is ongoing to test the efficacy of peripheral
intravenous injections of a combination of two monoclonal
antibodies that neutralize the biologic activity of IL4 and IL13
(NCT02494206). Further clinical studies are needed to develop
targeted therapies directed to improve lymphatic regeneration
and function, together with the modulation of inflammatory
pathways. An appropriate medical treatment combining physical
and molecularly targeted drugs administered early on after
surgery in high-risk individuals could become the key strategy
to prevent lymphedema formation.
CONCLUSIONS
BCRL is a complex and underdiagnosed condition, with
potentially devastating consequences on the quality of life
of breast cancer survivors. Several genetic, anatomical,
biological, and clinical factors might intervene in its
development, supporting the hypothesis of a multifactorial
etiopathogenesis. Impairment of the lymphatic system
embryogenetic differentiation mechanisms, anatomical
variations, alterations of the lymphatic pacemaking system,
mechanisms of phasic contractions of the lymphatic vessel, and
systemic inflammation might act synergistically. In addition,
mutations in genes encoding inter-cellular communication
have been linked to both primary and secondary lymphedema.
There is no evidence that genetic alterations related to the
different molecular subtypes of breast cancer could influence
BCRL pathogenesis. On the other hand, medical, surgical, and
radiation therapies are crucial factors in its development and
progression. Further research is needed in order to clarify,
according to a novel multidisciplinary approach, the strict
correlation between clinical and biological aspects of BCRL. The
identification of specific molecular targets, novel biomarkers, and
validated risk stratification tools could prove significantly crucial,
bringing us closer to achieving the goal of precision medicine
for BCRL.
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